Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches

Figure 1

Treatment with anti-IL17A significantly reduced lung and bone metastasis in SKG mice orthotopically injected with GFP positive 4 T1 BC cells. A: Percentage of lung metastasis in 4 T1 tumor-bearing SKG mice ± treatment and in 4 T1 tumor-bearing non-arthritic Balb/C mice. Statistical test based on a normal approximation: The difference between untreated and IgG treated versus anti-IL-17 treated is significant (*p = 0.006) and difference between untreated SKG + 4 T1 versus Balb/C + 4 T1 is also significant (**p = 0.001). Bi-iii: Representative images of GFP positive 4 T1 cells in lungs with no treatment (i), control IgG antibody treatment (ii) or anti-IL17A antibody treatment (iii). C: Percentage of bone metastasis in 4 T1 tumor-bearing SKG mice ± treatment and in 4 T1 tumor-bearing non-arthritic Balb/C mice. Assuming normal approximation, the difference between IgG control and anti- IL-17 treated group is significant (*p = 0.03) and difference between untreated SKG + 4 T1 and Balb/C + 4 T1 is also significant (**p = 0.001). Significance was not reached between untreated SKG + 4 T1 and IL-17A treated group although lower numbers of mice developed bone metastasis with anti-IL-17A antibody treatment. Di-iii: Representative X-ray images of metastatic bone lesions in 4 T1 tumor bearing SKG mice with no treatment (i) 4 T1 tumor bearing SKG mice treated with control IgG antibody (ii) or anti-IL-17A antibody treatment (iii) Arrows point to a metastatic site in the proximal humerus; note the prominent lucency in the proximal region, reflecting extensive bone loss at this site . (A-D: N = 10 mice). Ei-iii: Representative images of pancytokeratin staining of bone tissue to confirm metastasis in 4 T1 tumor bearing SKG mice with no treatment (i) 4 T1 tumor bearing SKG mice treated with control IgG antibody (ii) or anti-IL-17A antibody treatment (iii).

Back to article page